Latest News on VERA

Financial News Based On Company


Advertisement
Advertisement

Three holders report the same 7 million-share passive stake in Vera Therapeutics (VERA).

https://www.stocktitan.net/sec-filings/VERA/schedule-13g-a-vera-therapeutics-inc-amended-passive-investment-discl-4f53cb6c5cea.html
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have each reported a beneficial ownership of 7,000,000 Class A common shares, representing 9.71% of Vera Therapeutics (VERA). This passive stake was disclosed in an amended SCHEDULE 13G/A filing, noting the ownership as of September 30, 2026. The percentage is calculated based on 72,063,335 common shares outstanding as of July 29, 2026.

A fund adviser reports sole voting power over 5.64 million Vera Therapeutics (VERA) shares.

https://www.stocktitan.net/sec-filings/VERA/schedule-13g-a-vera-therapeutics-inc-amended-passive-investment-discl-849f1efdf651.html
Avoro Capital Advisors LLC and Behzad Aghazadeh have each reported beneficial ownership of 5,635,000 shares of Vera Therapeutics (VERA) Class A common stock, representing 7.82% of the class. Both entities hold sole voting and dispositive power over these shares. The shares were acquired for investment purposes on behalf of Avoro Life Sciences Fund LLC, with Aghazadeh serving as the portfolio manager and controlling person for Avoro.

Weekly Recap: ORIGIN 3 meets endpoints and TRUTAKNA sales, FDA filing

https://www.tradingview.com/news/tradingview:d5d07afb8c863:0-weekly-recap-origin-3-meets-endpoints-and-trutakna-sales-fda-filing/
Vera Therapeutics (NASDAQ:VERA) announced that its TRUTAKNA drug met all endpoints in the ORIGIN 3 trial, significantly reducing annual eGFR decline and kidney progression risk. The company has filed for full FDA approval, with a decision expected in mid-2027. Initial TRUTAKNA sales were $10.3 million, though the company reported a third-quarter loss and increased cash use due to launch-related investments.

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://www.globenewswire.com/news-release/2026/11/06/3397887/0/en/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Vera Therapeutics, Inc. announced that its Compensation Committee granted inducement awards to three new employees on November 2, 2026. These awards include non-qualified stock options for 14,900 shares and restricted stock units (RSUs) for 7,450 shares of Class A common stock, approved under the company's 2024 Inducement Plan. The grants are intended to incentivize the new employees and comply with Nasdaq Listing Rule 5635(c)(4).

Vera Therapeutics, Inc. (VERA) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/VERA/
This article provides a comprehensive overview of Vera Therapeutics, Inc. (VERA), including its stock price, news, and historical data. It details the company's focus on developing treatments for immunological diseases, featuring key pipeline assets like atacicept and MAU868. The report also covers performance metrics, analyst ratings, and financial highlights.
Advertisement

Vera Therapeutics (NasdaqGM:VERA) Stock Forecast & Analyst Predictions

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/future
Vera Therapeutics is forecast to grow earnings by 64.2% and revenue by 57.9% per annum, with EPS expected to grow by 64.3% per annum, despite a projected -145.1% return on equity in three years. Analysts have revised revenue estimates downwards for 2026 and no longer expect the company to break even in the foreseeable future. The company recently announced positive final efficacy analysis from its ORIGIN 3 trial for TRUTAKNA in IgA nephropathy, leading to plans for a supplemental BLA filing in Q4 2026 for full FDA approval.

VERA Sentiment

https://stocktwits.com/symbol/VERA/sentiment
This article provides an overview of the sentiment surrounding Vera Therapeutics Inc (VERA) based on social media chatter. It presents metrics such as sentiment score, message volume, and participation ratio, indicating whether users are bullish or bearish, the total discussion volume, and the number of unique accounts involved. All these metrics are displayed as "N/A" for the last score, with historical data requiring sign-up or login.

Five new hires at Vera Therapeutics received share options and awards that vest over four years.

https://www.stocktitan.net/news/VERA/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-iew3ko93mzd2.html
Vera Therapeutics granted inducement awards consisting of stock options for 16,700 Class A shares and restricted stock units (RSUs) for 8,350 Class A shares to five new employees on September 29, 2026. These awards, approved under Nasdaq Listing Rule 5635(c)(4), have an exercise price of $32.38 per share for options and both types vest over four years, subject to continued employment. This news highlights the company's compensation strategy and potential future share dilution.

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://www.globenewswire.com/news-release/2026/10/02/3374017/0/en/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Vera Therapeutics announced inducement grants consisting of non-qualified stock options and restricted stock units to five new employees under its Inducement Plan. These awards, approved by the Compensation Committee, are material inducements for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The grants involve 16,700 shares of Class A common stock options and 8,350 shares of Class A common stock as RSUs, with specific vesting schedules tied to continued employment.

Weekly Recap: Q4 2026 sBLA filing for TRUTAKNA and Stock up ~2% to $34.76

https://www.tradingview.com/news/tradingview:e1300d3d21687:0-weekly-recap-q4-2026-sbla-filing-for-trutakna-and-stock-up-2-to-34-76/
Vera Therapeutics, Inc. announced plans to file an sBLA for TRUTAKNA with the FDA in Q4 2026, aiming for approval in 2027. The company reported early commercial success with over 350 patient starts in 10 weeks and initial payer policy uptake, which contributed to a 2% rise in its stock to approximately $34.76 after trial data release.
Advertisement

Vera Therapeutics (NASDAQ: VERA) CEO exercises options and sells shares under preset trading plan

https://www.stocktitan.net/sec-filings/VERA/form-4-vera-therapeutics-inc-insider-trading-activity-36017b5104f5.html
Vera Therapeutics' President and CEO, Marshall Fordyce, exercised stock options for 18,500 shares of Class A Common Stock at an exercise price of $2.8968 per share on September 15, 2026. Simultaneously, he sold all 18,500 shares at $37.00 per share under a Rule 10b5-1 trading plan. Following these transactions, Fordyce directly held 488,801 stock options and 235,244 shares of Class A Common Stock.

Vera Therapeutics (VERA) finance SVP adds 5,000 shares

https://www.stocktitan.net/sec-filings/VERA/form-4-vera-therapeutics-inc-insider-trading-activity-ba247bf33273.html
Joseph R. Young, SVP, Finance and Chief Accounting Officer of Vera Therapeutics (VERA), exercised stock options for 5,000 shares of Class A common stock on September 11, 2026, at an exercise price of $3.9396 per share. This transaction increased his direct common stock holdings to 80,754 shares, with 33,589 stock options remaining. The options had an initial cliff vesting of 25% on March 9, 2022, followed by monthly vesting.

Vera Therapeutics CEO Marshall Fordyce Executes 18,500 Share Sale Under 10b5-1 Trading Plan

https://kalkinemedia.com/us/news/announcements/vera-therapeutics-ceo-marshall-fordyce-executes-18500-share-sale-under-10b5-1-trading-plan
Vera Therapeutics CEO Marshall Fordyce exercised stock options and subsequently sold 18,500 shares of Class A Common Stock on September 2, 2026, under a pre-established Rule 10b5-1 trading plan. The shares were sold at a weighted-average price of $35.1158. Following these transactions, Fordyce directly holds 235,244 shares and retains 507,301 stock options.

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://www.globenewswire.com/news-release/2026/09/04/3356792/0/en/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Vera Therapeutics announced inducement awards to six new employees, consisting of non-qualified stock options to purchase 61,500 shares and restricted stock units (RSUs) underlying 30,750 shares of Class A common stock. These awards, granted on September 1, 2026, are part of the company's 2024 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $34.23 per share and vest over four years, as do the RSU awards, contingent on the employees' continued service.

What Vera Therapeutics (VERA)'s Widening Losses and Cash Burn Mean For Shareholders

https://www.sahmcapital.com/news/content/what-vera-therapeutics-veras-widening-losses-and-cash-burn-mean-for-shareholders-2026-08-18
Vera Therapeutics (VERA) reported a significant widening of net losses in Q2 2026 and the first half of 2026, reaching US$109.47 million and US$230.51 million respectively, leading to increased cash burn and pressure on per-share results. This performance highlights the high costs associated with developing its drug TRUTAKNA and the broader atacicept program, raising concerns about funding risk and potential dilution. Despite the financial challenges, the company's investment narrative hinges on the eventual commercial viability of TRUTAKNA and successful navigation of regulatory hurdles.
Advertisement

Kynam Capital (VERA) now holds 4.01% beneficial stake in Vera Therapeutics

https://www.stocktitan.net/sec-filings/VERA/schedule-13g-a-vera-therapeutics-inc-amended-passive-investment-discl-b9024f290eac.html
Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang have reported a 4.01% beneficial ownership stake in Vera Therapeutics, Inc. Class A common stock. This represents 2,890,059 shares with shared voting and dispositive power. The filing indicates that their ownership is 5 percent or less of the class.

Is Vera Therapeutics (VERA) Undervalued On FDA Approval For TRUTAKNA?

https://www.sahmcapital.com/news/content/is-vera-therapeutics-vera-undervalued-on-fda-approval-for-trutakna-2026-08-12
Vera Therapeutics (VERA) received accelerated FDA approval for TRUTAKNA for IgA nephropathy, but its share price has fallen recently despite strong long-term returns. The company is currently loss-making and trades at a P/B ratio of 5.4x, which is below peers but above the broader biotech industry. A Simply Wall St DCF model suggests the stock is significantly undervalued compared to its estimated future cash flow value.

Vera Therapeutics CEO Marshall Fordyce sells $679,747 in stock

https://m.investing.com/news/insider-trading-news/vera-therapeutics-ceo-marshall-fordyce-sells-679747-in-stock-93CH-4856594?ampMode=1
Marshall Fordyce, CEO of Vera Therapeutics, sold $679,747 worth of Class A Common Stock on May 12, 2026, after exercising stock options. These transactions were executed under a pre-arranged trading plan, and he now directly owns 235,244 shares and holds 590,551 stock options. The company recently reported Q2 2026 financial results, received accelerated FDA approval for Trutakna, and saw several analyst rating adjustments.

Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock

https://m.investing.com/news/insider-trading-news/vera-therapeutics-president-and-ceo-marshall-fordyce-sells-196m-in-stock-93CH-4856595?ampMode=1
Marshall Fordyce, President and CEO of Vera Therapeutics, Inc. (NASDAQ:VERA), sold 46,250 shares of the company’s Class A Common Stock for approximately $1.96 million on July 7, 2026, while concurrently acquiring the same number of shares through stock option exercises. The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, with the stock price having declined significantly since the transactions. The company recently received accelerated FDA approval for its drug Trutakna and reported Q2 2026 financial results showing a narrower loss per share than estimated.

Vera Therapeutics (VERA) CEO trades 18,500 shares via 10b5-1 option exercise

https://www.stocktitan.net/sec-filings/VERA/form-4-a-vera-therapeutics-inc-amended-insider-trading-activity-6e89358a9ba2.html
Vera Therapeutics' President and CEO, Marshall Fordyce, exercised options for 18,500 shares of Class A Common Stock at $2.8968 per share and subsequently sold all 18,500 shares on June 23, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on January 9, 2026, with the shares sold at a weighted-average price of $37.9311 for 18,412 shares and $38.43 for the remaining 88 shares. This transaction was disclosed in an amended Form 4 filing correcting previous beneficial ownership amounts.
Advertisement

Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock

https://m.investing.com/news/insider-trading-news/vera-therapeutics-president-and-ceo-marshall-fordyce-sells-701769-in-stock-93CH-4856592?ampMode=1
Vera Therapeutics president and CEO Marshall Fordyce sold 18,500 shares of Class A Common Stock for $701,769 on June 23, 2026, as part of a pre-arranged trading plan, while also exercising options for an equal number of shares. The company, valued at $2.16 billion, has a "Weak" financial health rating due to burning through cash, despite recent FDA approval for Trutakna and varying analyst price targets. Following these transactions, Fordyce holds 235,244 shares and 572,051 stock options.

Vera Therapeutics (VERA) CEO option exercise and 18,500-share sale under 10b5-1 plan

https://www.stocktitan.net/sec-filings/VERA/form-4-a-vera-therapeutics-inc-amended-insider-trading-activity-063c933844df.html
Vera Therapeutics (VERA) CEO Marshall Fordyce exercised stock options for 18,500 shares of Class A Common Stock at $2.8968 per share and subsequently sold all 18,500 shares in open-market transactions on May 12, 2026. The sales, totaling approximately $680K in gross proceeds, were executed under a pre-approved Rule 10b5-1 trading plan adopted on January 9, 2026. After these transactions, Fordyce beneficially owns 590,551 stock options and 235,244 shares of Class A Common Stock directly.

Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock

https://m.za.investing.com/news/stock-market-news/vera-therapeutics-president-and-ceo-marshall-fordyce-sells-196m-in-stock-93CH-4425925?ampMode=1
Vera Therapeutics President and CEO Marshall Fordyce sold approximately $1.96 million worth of company stock through a pre-arranged trading plan, while also exercising stock options. The company's stock has since declined by over 40% year-to-date. These transactions follow recent financial results, FDA approval for its drug Trutakna, and updated analyst ratings.

Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock

https://uk.investing.com/news/stock-market-news/vera-therapeutics-president-and-ceo-marshall-fordyce-sells-701769-in-stock-93CH-4829036
Vera Therapeutics President and CEO Marshall Fordyce sold 18,500 shares of the company's stock for $701,769 on June 23, 2026, pursuant to a pre-arranged trading plan. On the same day, Fordyce also exercised options to acquire 18,500 shares. Despite the stock's 41% year-to-date decline, InvestingPro suggests it is undervalued, though the company has a "Weak" financial health rating and is burning cash quickly.

Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock

https://www.investing.com/news/insider-trading-news/vera-therapeutics-president-and-ceo-marshall-fordyce-sells-196m-in-stock-93CH-4856595
Marshall Fordyce, President and CEO of Vera Therapeutics (NASDAQ:VERA), sold 46,250 shares of Class A Common Stock for approximately $1.96 million on July 7, 2026, while concurrently acquiring the same number of shares through stock options for $133,977. The sales were executed under a pre-arranged trading plan, and the company's stock has since fallen over 40% year-to-date, though InvestingPro analysis suggests it may be undervalued. This comes amidst other company news, including strong Q2 2026 financial results and FDA approval for its drug Trutakna.
Advertisement

Vera Therapeutics CEO Marshall Fordyce sells $679,747 in stock

https://www.investing.com/news/insider-trading-news/vera-therapeutics-ceo-marshall-fordyce-sells-679747-in-stock-93CH-4856594
Marshall Fordyce, CEO of Vera Therapeutics (NASDAQ:VERA), sold shares worth $679,747 on May 12, 2026, after exercising stock options. These transactions were carried out under a pre-arranged trading plan, leaving him with 235,244 shares and 590,551 stock options. The sale follows recent company news including FDA approval for Trutakna and varying analyst price targets.

Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock

https://www.investing.com/news/insider-trading-news/vera-therapeutics-president-and-ceo-marshall-fordyce-sells-701769-in-stock-93CH-4856592
Vera Therapeutics president and CEO Marshall Fordyce sold 18,500 shares of the company's Class A Common Stock for $701,769 on June 23, 2026, as part of a pre-arranged trading plan. This transaction followed the exercise of options to acquire an equal number of shares. The company, despite having a "Weak" financial health rating and analysts noting its cash burn, recently received accelerated FDA approval for its drug Trutakna, leading to raised price targets from several firms.

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://www.globenewswire.com/news-release/2026/08/07/3341383/0/en/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Vera Therapeutics announced inducement awards of non-qualified stock options and restricted stock units (RSUs) to its new Chief Regulatory Officer, Nancy Bowman, and two other new employees. These grants were made under the company's 2024 Inducement Plan and approved by the Compensation Committee as a material inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options and RSUs have specific exercise prices and vesting schedules over four years, subject to continued employment.

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://www.manilatimes.net/2026/08/08/tmt-newswire/globenewswire/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4/2401234
Vera Therapeutics announced inducement grants of non-qualified stock options and restricted stock units (RSUs) to new employees, including its new Chief Regulatory Officer, Nancy Bowman, M.D., Ph.D. These grants, made under the company's 2024 Inducement Plan, are consistent with Nasdaq Listing Rule 5635(c)(4) and are designed to incentivize continued employment. The awards vest over four years, subject to continuous service.

State Street Corporation (VERA) discloses 4.1M-share stake in Vera Therapeutics

https://www.stocktitan.net/sec-filings/VERA/schedule-13g-vera-therapeutics-inc-passive-investment-disclosure-5-5e39c3a84ef3.html
State Street Corporation has reported a beneficial ownership of 4,148,786 shares of Vera Therapeutics Inc. common stock, which represents a 5.8% stake in the company. The filing indicates that State Street holds shared voting power over 3,996,044 shares and shared dispositive power over all 4,148,786 shares, with no sole voting or dispositive power. This investment is managed through various investment adviser subsidiaries, including SSGA Funds Management, Inc. and several State Street Global Advisors entities.
Advertisement

Vera Therapeutics grants equity inducement awards to new hires

https://scanx.trade/stock-market-news/companies/vera-therapeutics-grants-equity-inducement-awards-to-new-hires/47681796
Vera Therapeutics Inc (NASDAQ: VERA) granted inducement equity awards to three new employees, including Chief Regulatory Officer Nancy Bowman, under Nasdaq Listing Rule 5635(c)(4). The awards, consisting of stock options and RSUs, are designed to attract key talent and vest over four years subject to continued service. This move aligns with the company's strategy to bolster its regulatory and operational capabilities, particularly for its commercial-stage product TRUTAKNA™.

Equity awards for Vera Therapeutics (VERA) Chief Regulatory Officer

https://www.stocktitan.net/sec-filings/VERA/form-4-vera-therapeutics-inc-insider-trading-activity-b67df4b96f15.html
Vera Therapeutics (VERA) Chief Regulatory Officer, Nancy Lee Boman, received equity awards comprising 63,011 stock options with an exercise price of $32.23 and 44,987 restricted stock units (RSUs) under the company's 2024 Inducement Plan. These awards are subject to vesting schedules based on continuous service, with the options expiring in 2036 and RSUs vesting quarterly from 2027 to 2030. The Form 4 filing indicates these grants were not part of a Rule 10b5-1 trading plan.

BlackRock (NYSE: BLK) discloses 5.34M-share Vera Therapeutics (VERA) stake

https://www.stocktitan.net/sec-filings/VERA/schedule-13g-a-vera-therapeutics-inc-amended-passive-investment-discl-7fac8dd32404.html
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 5,340,522 Class A shares of Vera Therapeutics, Inc. This stake represents 7.4% of Vera Therapeutics' outstanding Class A shares. BlackRock primarily holds sole voting power over 5,247,811 shares and sole dispositive power over 5,340,522 shares, with no individual client owning more than five percent of Vera's common shares.

The Bull Case For Vera Therapeutics (VERA) Could Change Following TRUTAKNA’s Accelerated FDA Approval - Learn Why

https://www.sahmcapital.com/news/content/the-bull-case-for-vera-therapeutics-vera-could-change-following-trutaknas-accelerated-fda-approval-learn-why-2026-07-16
Vera Therapeutics received accelerated FDA approval for TRUTAKNA (atacicept-vymj) to treat IgA nephropathy, targeting both BAFF and APRIL. This approval shifts the investment focus to the commercial launch, conversion to full approval, and safety management. Investors are weighing the potential for TRUTAKNA to become a durable franchise against the inherent clinical and regulatory uncertainties of accelerated approval.

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://finance.yahoo.com/healthcare/articles/vera-therapeutics-announces-inducement-grants-200500737.html
Vera Therapeutics announced inducement grants consisting of non-qualified stock options and restricted stock units to eight new employees. These awards are in accordance with Nasdaq Listing Rule 5635(c)(4) and are designed to incentivize new hires. The stock options and RSUs will vest over four years, subject to continued employment with the company.
Advertisement

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://www.globenewswire.com/news-release/2026/07/10/3325748/0/en/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Vera Therapeutics Inc. announced inducement awards for eight new employees, consisting of non-qualified stock options for 32,100 shares and restricted stock units for 16,050 shares. These awards, granted on July 6, 2026, under the company's 2024 Inducement Plan, are intended to be a material inducement for their employment as per Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $40.13 and both types of awards vest over four years, subject to continued employment.

New Vera Therapeutics employees receive $40.13 stock options in inducement plan

https://www.stocktitan.net/news/VERA/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-k6dimb60x7zk.html
Vera Therapeutics announced that its Board Compensation Committee granted inducement equity awards to eight new employees on July 6, 2026. These awards include non-qualified stock options for 32,100 Class A shares with an exercise price of $40.13 and RSUs for 16,050 Class A shares, both vesting over four years. The grants are in accordance with Nasdaq Listing Rule 5635(c)(4).

Vera Therapeutics (VERA) Wins FDA Approval For TRUTAKNA, Is The Stock Fully Priced?

https://www.sahmcapital.com/news/content/vera-therapeutics-vera-wins-fda-approval-for-trutakna-is-the-stock-fully-priced-2026-07-09
Vera Therapeutics (VERA) has received accelerated FDA approval for TRUTAKNA, its first commercial product for primary IgA nephropathy. Despite a year-to-date share price decline of 12.73%, the company has seen a 1-month rebound of 33.39% following the approval and a 74.25% one-year return. While its price-to-book ratio of 6.1x suggests it's expensive compared to the broader US Biotechs sector, internal fair value estimates and discounted cash flow models suggest the stock might be undervalued.

Vera Therapeutics CEO Fordyce Marshall sells shares worth $1.96 million

https://www.investing.com/news/insider-trading-news/vera-therapeutics-ceo-fordyce-marshall-sells-shares-worth-196-million-93CH-4784956
Vera Therapeutics CEO Fordyce Marshall sold approximately $1.96 million worth of Class A Common Stock on July 7, 2026, under a pre-arranged trading plan. Despite the sale, the stock is considered undervalued by InvestingPro, and the company recently received FDA approval for its drug Trutakna for IgA nephropathy, leading to several analyst price target increases. Marshall still holds a substantial number of direct and indirect shares in the biotech company.

Vera Therapeutics CEO Fordyce Marshall sells shares worth $1.96 million

https://m.uk.investing.com/news/stock-market-news/vera-therapeutics-ceo-fordyce-marshall-sells-shares-worth-196-million-93CH-4764760?ampMode=1
Vera Therapeutics CEO Fordyce Marshall sold Class A Common Stock valued at approximately $1.96 million on July 7, 2026, through a pre-arranged trading plan. Despite these sales, Marshall retains a significant direct and indirect stake in the company. This news follows Vera Therapeutics' recent accelerated FDA approval for its drug Trutakna, leading to several analyst price target increases.
Advertisement

Vera Therapeutics (VERA) CEO preplanned sale of 46,250 shares reported

https://www.stocktitan.net/sec-filings/VERA/form-4-vera-therapeutics-inc-insider-trading-activity-e6346d9c2fc5.html
Vera Therapeutics CEO Marshall Fordyce reported the sale of 46,250 shares of Class A common stock on July 7, 2026, through a pre-planned trading arrangement (Rule 10b5-1(c)). The shares were sold at weighted-average prices between $40.39 and $43.97. Following these transactions, Fordyce retains significant holdings, both direct and indirect, in the company.

Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner

https://www.sahmcapital.com/news/content/vera-therapeutics-announces-appointment-of-nancy-boman-as-chief-regulatory-officer-and-planned-retirement-of-william-turner-2026-07-09
Vera Therapeutics has announced that Nancy Boman, M.D., Ph.D., will take over as Chief Regulatory Officer, succeeding William Turner, who will retire and transition to a Strategic Advisor role in Q3 2026. Turner's tenure included the accelerated approval of TRUTAKNA™ for IgA nephropathy. Dr. Boman brings over 25 years of regulatory affairs experience, having held similar roles at Kyverna Therapeutics, Adicet Bio, Encoded Therapeutics, and Novartis Gene Therapies.

Vera Therapeutics (VERA) Proxy filing Summary

https://quartr.com/events/vera-therapeutics-inc-vera-proxy-filing_F3sCt02f
Vera Therapeutics (VERA) has scheduled its annual meeting for May 21, 2026, where shareholders will vote on the election of three Class II directors, the ratification of KPMG LLP as the 2026 auditor, and an advisory vote on executive compensation. Only Class A common stock holders as of March 24, 2026, are eligible to vote. The company's board consists of ten independent and one executive director, with a focus on diversity and expertise.

VERA Stock Holds Gains As CEO Trims Stake In Form 4 Sale

https://stockstotrade.com/news/vera-therapeutics-inc-vera-news-2026_07_07/
Vera Therapeutics Inc. (NASDAQ: VERA) stock has risen by 9.52% due to positive clinical trial progress, despite its CEO, Marshall Fordyce, selling 18,500 shares for $701,769. Fordyce still retains a significant stake of over 420,000 shares, suggesting the sale is a profit-taking move rather than a sign of diminishing confidence. The company currently faces a substantial net loss and high R&D spending, but is supported by a strong cash balance of $596.8 million and a high current ratio, providing a long runway for its developmental projects.

What's Going on with Vera Therapeutics Stock on Monday?

https://www.sahmcapital.com/news/content/whats-going-on-with-vera-therapeutics-stock-on-monday-2026-07-06
Vera Therapeutics Inc. (NASDAQ: VERA) stock is gaining momentum as the company awaits a key FDA decision for its rare kidney disease drug, atacicept. The FDA's action date is July 7 for accelerated approval of atacicept for IgA Nephropathy, supported by positive data from the ORIGIN 3 trial. Novartis AG (NYSE: NVS) remains a competitor with its recently approved drug Vanrafia for the same condition.
Advertisement

Vera Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:VERA)

https://www.tradingview.com/symbols/NASDAQ-VERA/forecast-actuals-and-estimates/
This article provides key financial data and analyst insights for Vera Therapeutics, Inc. (NASDAQ:VERA). It covers the stock's recent performance, analyst price targets (ranging from $35.00 to $110.00), historical highs and lows, market capitalization, upcoming earnings reports, and volatility. The company's last earnings report showed a surprise of -27.22%, and it does not pay dividends.

Vera Therapeutics (VERA) CEO sells 18,500 shares under 10b5-1 plan

https://www.stocktitan.net/sec-filings/VERA/form-4-vera-therapeutics-inc-insider-trading-activity-514f82bd1df3.html
Vera Therapeutics (VERA) CEO Marshall Fordyce sold a total of 18,500 shares of Class A Common Stock on June 23, 2026, under a pre-arranged Rule 10b5-1(c) trading plan adopted on January 9, 2026. The sales were executed at weighted-average prices of $38.43 and $37.93 per share. Following these transactions, Fordyce directly holds 198,244 shares and indirectly holds an additional 222,030 shares through a trust and a GRAT.

Vera Therapeutics president and CEO Fordyce Marshall sells $701,769 in stock

https://m.uk.investing.com/news/stock-market-news/vera-therapeutics-president-and-ceo-fordyce-marshall-sells-701769-in-stock-93CH-4743230?ampMode=1
Fordyce Marshall, President and CEO of Vera Therapeutics, sold 18,500 shares of company stock for over $700,000, executed under a pre-arranged trading plan. This sale follows a period of strong stock performance for Vera Therapeutics, which recently announced positive regulatory developments for its Phase III ORIGIN 3 study. Analysts have reacted positively to these updates, reiterating strong ratings and price targets for the company.

Vera Therapeutics president and CEO Fordyce Marshall sells $701,769 in stock

https://www.investing.com/news/insider-trading-news/vera-therapeutics-president-and-ceo-fordyce-marshall-sells-701769-in-stock-93CH-4759118
Fordyce Marshall, President and CEO of Vera Therapeutics, Inc. (NASDAQ:VERA), sold 18,500 shares of the company's Class A Common Stock for $701,769 on June 23, 2026. This transaction was part of a pre-arranged 10b5-1 trading plan and occurred amidst strong stock performance, with VERA shares returning 69% over the past year. Following the sale, Marshall still holds a significant number of shares directly and indirectly, while analysts have reiterated positive ratings for the company due to regulatory developments for its drug atacicept.

Vera Therapeutics (VERA) Is Up 10.7% After Accelerated FDA Timeline For Atacicept IgAN Filing - Has The Bull Case Changed?

https://www.sahmcapital.com/news/content/vera-therapeutics-vera-is-up-107-after-accelerated-fda-timeline-for-atacicept-igan-filing-has-the-bull-case-changed-2026-06-19
Vera Therapeutics recently announced an accelerated FDA timeline for the ORIGIN 3 eGFR analysis for atacicept in IgA nephropathy, supporting a planned supplemental Biologics License Application in Q4 2026. This development clarifies the regulatory pathway and could fast-track full approval, influencing the company's investment narrative. Despite the positive news, Vera Therapeutics remains loss-making with increasing operating expenses, highlighting continued execution risk and potential future funding needs.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement